Check for updates

Review Article

Amniotic fluid characteristics and its application in stem cell therapy: A review

Hoda Shamsnajafabadi Ph.D., Zahra-Soheila Soheili Ph.D.

National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

Corresponding Author:

Zahra-Soheila Soheili; Ministry of Science-Research and Technology, National Institute of Genetic Engineering and Biotechnology, Pajoohesh Blvd., Km 17 Tehran-Karaj Highway, Tehran, Iran.
Postal Code: 1497716316
Tel: (+98) 21 44787379
Email: soheili@nigeb.ac.ir

ORCID:

https://orcid.org/0000-0003-1292-465x

Abstract

Amniotic fluid (AF) is a clear yellow fluid that surrounds the fetus during pregnancy. The amniotic sac consists of 2 layers: the amnion and the chorion. Osmotic and hydrostatic forces cause the maternal plasma to pass through the fetal skin and generate the AF. AF allows the fetus to grow inside the uterus, supports it from injuries, retains consistent pressure and temperature, and enables the exchange of body chemicals with the mother. At first, it consists of water and electrolytes but after the 12-14th wk the liquid also contains carbohydrates, proteins, lipids, phospholipids, urea, hormones, and some biochemical products. AF appearance is characterized by the grade of cloudiness and the number of flakes of the vernix. The volume of AF increases with the fetus's growth. Its appearance depends on the gestational age. In addition to differentiated cells, stem cells are also found within the AF. These cells express embryonic-specific cell markers and bear high self-renewal capacity and telomerase activity. AF stem cells possess the potential to differentiate into osteogenic, cardiac, skeletal muscle, lung, neuronal, kidney, bone, cartilage, ovarian and hepatic cells in vitro. They represent a great promise in regenerative medicine for the reconstruction of bio-artificial tissues and organs in vivo. The purpose of this paper was to briefly review the development and function of AF and the application of its stem cells in cell therapy.

Key words: Amniotic fluid, Stem cells, Differentiation, Regeneration, Tissue engineering.

OPEN ACCESS

1. Introduction

Amniotic fluid (AF) is a complex physiological and dynamic biological fluid that surrounds the fetus during pregnancy. It provides mechanical protection and the nutrients required for fetal growth and wellbeing. After about 12 days of pregnancy, an amniotic membrane forms and lines the fetal cavity, while contemporary AF begins to fill the amniotic sac (1). In this review, we explain the features of AF stem cells (AFSCs). We focus on their ability to differentiate in vitro and their potential application for tissue regeneration in vivo.

1.1. AF sources

In the first trimester of pregnancy, the osmolality of the AF and maternal plasma are the same, which suggests that the maternal plasma generates the AF (2). Until the 22-25th wk, the fetal skin is non-keratinized which allows AF to penetrate the skin and the surfaces of the placenta, amnion, and umbilical cord, which are freely penetrable

to water and solutes (3). After the 24th wk, the surfaces of the nose and mouth exchange fluid, but this is not the main origin of AF (4). In the latter half of pregnancy, the main origins of AF are from fetal urine production, pulmonary excretion, fetal swallowing, transmembranous movement among the amnion and chorion, and intramembranous movement between the fetal blood and the placenta (Table I) (5-9).

1.2. AF function

AF has vital functions such as nourishment, and antimicrobial and mechanical protection of the fetus during pregnancy. The most important roles of AF are as follows:

1. Shock absorber: AF protects the fetus from mechanical trauma (10).

2. Body parts development: AF helps the growth of the external body parts such as fingers and toes and the development of the lungs and the digestive systems by circulating freely within the womb and lubricating each part of the body.

Table I. The main origins of AF near the full term of pregnancy

Author, year (Ref)	AF origins	Amount (ml/day)	Direction
Van Otterlo *et al.*, 1977 (7)	Fetal urine	800-1000	Fetus to AF
Abramovich *et al.*, 1979 (8)	Fetal swallowing	500-1,000	AF to fetus
Brace, 1997 (9)	Intramembranous pathway	200-500	AF to fetus
	Fetal lung	340	AF to fetus and fetus to AF
	Transmembranous pathway	10	AF to fetus

AF: Amniotic fluid

3. Antibacterial activity: AF plays a significant role in the baby's natural immune system. It contains different antimicrobial substances including lactoferrin, lysozyme, bactericidal/permeability-increasing protein, a-defensins (HNP1-3), psoriasin (S100A7),

calprotectin, cathelicidin (LL-37), and secretory leukocyte protease inhibitor, which contribute to the natural immune system in babies. These antimicrobials protect the baby from various bacteria, protozoa, fungi, and viruses (11).

4. Nutrition delivery: AF is rich in carbohydrates, hormones, lipids, lactate, electrolytes, enzymes, proteins, peptides and pyruvate which support fetal growth (4).

5. Temperature stabilizer: AF stabilizes the temperature to protect the fetus from extreme temperature changes (12).

1.3. AF composition

AF initially consists of water from the mother but gradually, a larger proportion is made up of the baby's urine. It also consists of different kind of nutrients, hormones, and biochemical products (Table II) (13-15).

Table II. AF composition of nutrients, hormones and biochemical products

Author, year (Ref)	AF composition	Components
Underwood *et al.*, 2005 (4)	Nutrients	Proteins, amino acids, lactate, pyruvate, peptides, carbohydrates, lipids, phospholipids, urea, and electrolytes
Dawood, 1977 (13)	Hormones	Prolactin, growth hormone, human chorionic somatomammotropin, placental hormone, human chorionic corticotropin, human chorionic gonadotropin, human chorionic thyrotropin, and placental luteinizing hormone-releasing factor
Oliveira *et al.*, 2002 (14) Bauk *et al.*, 1996 (15)	Biochemical products	Creatinine, N-acetyl-ß-D-glucosaminidase, urea, potassium, uric acid, ß2-microglobulin, glucose, sodium, phosphorus, calcium, and albumin

AF: Amniotic fluid

Biochemical products are interchanged between the mother and fetus. The value of some biochemical markers such as ß2-microglobulin, glucose, and uric acid present significant correlations with gestational age and creatinine, while other biochemical markers like urea, potassium, and phosphorus present mild correlations with age and creatinine. ß2-microglobulin, glucose, and uric acid are significant indicators of the function and maturation of fetal kidneys (Figure 1) (14). From the 14th-16th wk of gestation, the AF is composed of some growth factors that promote the growth, attachment, polarity, and migration of cells in culture. We previously demonstrated that AF was able to advance the trans differentiation of retinal pigmented epithelium cells into rod photoreceptors, retinal progenitor, and retinal ganglion cells (16-18).


Figure 1. Values of biochemical markers of AF throughout gestation, data was obtained from Oliveira et al., 2002 article (14).

1.4. AF appearance

AF appearance is determined by the degree of cloudiness and the number of flakes over the pregnancy. Flakes are released from the fetal skin and depend on the maturation of the central nervous system of the fetus. Thus, the appearance of the AF is an indicator of fetal maturity. Macroscore is a system that categorizes the summation of flake quantity and the cloudiness degree as a score ranging from 0-6, from no flakes or no cloudiness to a large number of flakes and very cloudy fluid. Thus, the microscore can fluctuate between 0 and 12 (Figure 2).

At the end of the 32nd wk of pregnancy, the mean macroscore is 0; the AF is clear and does not have any flakes. By the 36th wk, the average macroscore is 1-2 as the AF has some flakes and carries a trace of cloudiness. After that the score increases until the 40th wk of pregnancy; by this wk the mean score is 8 ± 2.6 as the AF contains a moderate amount of flakes and is cloudy. The mean macroscore is about 8 ± 3.2 in the 41st wk, and thereafter the score increases until 9.3 ± 2.5 in the 42nd wk. By this wk it has a large number of flakes and is very cloudy (Figure 2) (19).

Figure 2. Microscore of AF during pregnancy, data was obtained from Verpoest MJ, 1976 article (19).

1.5. AF volume (AFV)

AFV can be measured directly at the time of cesarean or by uterine hysterotomy, or indirectly by dye-dilution techniques or sonography. Because direct and indirect techniques are time-consuming and invasive and may require laboratory support, AFV is commonly estimated by ultrasound (20). The advantages of sonography are that it is easy to carry out and teach, and it can be reproduced (21).

At the 12th wk of gestation, the average AFV is about 60 ml and by the 16th wk, it becomes 175 ml. In the 20th and 30th wk, there is a volume of 300 and 600 ml, respectively. AFV increases regularly during pregnancy until 400-1200 ml at 34-38 wk. After 38 wk, AFV decreases to 800 ml by the 40th wk. After 43 wk, this volume diminishes to 250 ml (22).

Oligohydramnios occurs when there is an AFV < 200-500 ml, which is detected by ultrasound (23). This can be due to idiopathic

underproduction or loss of fluid. Underproduction can be related to urinary tract obstruction, dysfunctional kidneys, maternal dehydration, or abnormal placental function (5). Loss of AF might happen due to rupture of surrounding membranes (24). Maternal hydration affects idiopathic oligohydramnios (25), so oral hydration is a noninvasive, easily accessible intervention to treat it (26). Oligohydramnios can cause fetal lung hypoplasia and contracture malformations (27). It can also increase the risk of non-reassuring fetal heart rate patterns, cesarean delivery, meconium aspiration, neonatal intensive care unit admission, and mortality (28). It has been estimated that 13.0% and 9.8% of pregnancies with oligohydramnios are associated with chromosomal anomalies and renal anomalies, respectively (29). The gestational age influences oligohydramnios management. If discovered after 37 wk of gestational age, it cannot induce premature labor. But it causes a significant increase in the risk of the fetus needing an operative delivery. It is increased the induction rate (56%) and cesarean rate (57%), as well as a higher risk of perinatal mortality (30).

An AFV of greater than 2000 ml, detected by ultrasound, indicates polyhydramnios (31). Chromosomal abnormalities, non-immune hydrops, twin-twin transfusion syndrome, and diabetes can cause polyhydramnios (32). Pregnancies with polyhydramnios are associated with a higher risk of premature birth, macrosomia, non-reactive non-stress tests, cesarean delivery, perinatal morbidity, and congenital anomalies (33). The rate of congenital malformations in polyhydramnios is 2.3% compared to 0.13% in cases of normal AF. Congenital malformation increases the risk of respiratory distress and hypoglycemia (34).

Polyhydramnios is related to fetal macrosomia and maternal pre-gestational/gestational diabetes (35). Polyhydramnios can be managed by sonographic evaluation for anatomical causes, TORCH serology testing, evaluation for maternal diabetes, and consideration of isoimmunisation if it is detected early. All the above should be considered, excluding an anatomical evaluation, if polyhydramnios is detected late (36).

1.6. Amniotic fluid stem cells (AFSCs)

AF is bordered by the amniotic membrane and the embryo's skin on one side, and the embryonic urinary tract, digestive tract, and respiratory ducts on the other side. AF has different embryonic cells from the 3 embryonic germinal layers (37). The fetal origin of these cells is represented by karyotype analysis (38). AF has fully differentiated cells, precursor and multipotent stem-like cells (39).

In 1993, hematopoietic progenitor cells were found in the AF before the 12th wk of gestation. In 1996, stem cells were found to be present in AF when they were cultivated in the supernatant of rhabdomyosarcoma cell lines and expressed dystrophin as a skeletal muscle protein (40). In 2003, mesenchymal stem cell markers' (Cluster of Differentiation (CD 90), CD105, CD73, CD44) expression of AF-derived cells was confirmed. These can differentiate into osteocytes, adipocytes, and fibroblasts (41). Prusa et al. demonstrated that AF-derived cells express Oct-4 similar to embryonic carcinoma cells, embryonic stem cells, and embryonic germ cells (42). In 2015, it was confirmed that some AF cells activate Rex-1 promoters like undifferentiated embryonic stem cells (43). In 2009, CD117 (c-Kit) immunoselection marker expression in AFSCs

was detected (44). This marker plays a significant role in melanogenesis, gametogenesis and hematopoiesis, and presents on primordial germ cells, human embryonic cells and many somatic stem cells (45).

1.7. Characteristics of AFSCs

AFSCs grow easily, have extensive self-renewal capabilities and appear phenotypically and genetically stable in culture (46). They can present with various morphologies from a fibroblast-like shape to an oval-round shape. They possess great proliferative properties with an average of over 250 population doublings in 36 hr and the clonogenic potential (86 $\pm$ 4.3 colonies) in culture (47).

Early pregnancy (first trimester) human AFSCs have 82% phenotype homology in transcriptome identity with embryonic stem cells (48). They are a heterogeneous population of 8-15 μm size. Like pluripotent and embryonic stem cells, the smaller cells make colonies in culture and represent c-Myc, octamer-binding transcription factor 4 (Oct-4), Homeobox transcription factor (Nanog), Kruppel like factor 4 (Klf4), sex determining region Y (SRY), SRY-box 2 (Sox2), Stage-specific embryonic antigen-4 (SSEA4), T cell receptor alpha-60 (Tra-1-60), SSEA3, Tra-1-8, and alkaline phosphatase (ALP) expression. The primordial germ cell origin of first-trimester AFSCs has been confirmed with CD117, SSEA3, c-Kit, FGF-8, DAZL, NANOS, VASA, SSEA1, Sox17, STELLA, FRAGILIS, and PUM2 expression (49). As well as, first-trimester AFSCs present high levels of mesenchymal stem cell markers expression including CD29, CD73, CD44, CD90, and CD105. Human leucocyte antigen (HLA) expression of these cells is low for class I

and negative for class II. They form embryoid bodies in vitro but do not form teratomas when injected in immunocompromised mice (50).

Second- and third-trimester human AFSCs show c-Myc, Oct-4 and SSEA4 expression while, they do not have Nanog, Klf4 SSEA3, Tra-1-60, Tra-1-81, or ALP expression. CD44, CD29, CD73, CD105, CD90, CD166, CD146 as MSC markers are expressed at high levels in AFSCs. These cells express HLA class I (HLA-ABC), but they do not express HLA class II (HLA-DR). When second-trimester AFSCs are transplanted in immunocompromised mice, they cannot form embryoid bodies and do not form teratomas. They show a low rate of chromosomal instability in both early- and long-term culture in vitro (51).

Similar to first-trimester AFSCs, 2nd-trimester AFSCs are of fetal origin and express migratory primordial germ cell markers (52). Any expression of hematopoietic markers CD45, CD34, CD31 and CD14 are not detected in AFSCs of any gestational age (43, 53). Second-trimester AFSCs can differentiate into bone, cartilage, muscle, fat, hepatic or neural stem cells, and dopaminergic neurons. The characteristics of AF cells are varied based on gestational age (54). Hematopoietic progenitor cells in AF can be initially obtained from a woman who is 12 wk pregnant. These cells probably originate from the yolk sac (55). During wk 14 of pregnancy, pluripotent stem cells are detected in the AF (42). From the 19th wk, the AF contains a population of mesenchymal stem cells that has the ability to differentiate into adipocytes, neurons, and osteocytes with a high proliferation rate (56). Neural progenitor cells are detected at wk 15-17 of pregnancy (57). The number of AF cells increases with gestational

age, while in pathological conditions such as urogenital atresia and spina bifida low counts and extra counts occur, respectively (Table III) (58-62).

Table III. Gene expression profile of AFSCs

Author, year (Ref)	Markers	Antigen or CD	First trimester	Second and third trimester
Loukogeorgakis *et al.*, 2017 Cananzi *et al.*, 2009 Guillot *et al.*, 2007 Baghaban Eslaminejad *et al.*, 2012 (59-62)	Stem cell	Oct4	+	+
		Nanog	+	−
		Sox2	+	−
		SSEA4	+	+
		c-Myc	+	+
		Tra-1-60	+	−
		SSEA3	+	−
		Tra-1-81	+	−
		ALPL	+	−
		Klf4	+	−
	Mesenchymal	CD29	+	+
		CD44	+	+
		CD73	+	+
		CD90	+	+
		CD105	+	+
		CD166	+	+
		CD146	+	+
	Hematopoietic	CD45	−	−
		CD34	−	−
		CD31	−	−
		CD14	−	−
	MHC	HLA class I	+	+
		HLA class II	−	−

AFSCs: Amniotic fluid stem cells, CD: Cluster of differentiation, Oct4: Octamer-binding transcription factor 4, Nanog: Homeobox transcription factor nanog, Sox2: Sex determining region Y-box 2, SSEA4: Stage-specific embryonic antigen-4, c-Myc: A family of regulator genes and proto-oncogenes that code for transcription factors, Tra-1-60: A cell surface antigen, expressed along with SSEA-3, SSEA-4 and TRA-1-81 in human embryonic stem cells, SSEA3: Stage-specific embryonic antigen 3, Tra-1-81: A cell surface antigen expressed along with SSEA-3, SSEA-4 and TRA-1-60, ALPL: Provides instructions for making an enzyme called tissue-nonspecific alkaline phosphatase, Klf4: Kruppel like factor 4, MHC: Major histocompatibility complex, HLA: Human leucocyte antigen

1.8. AFSCs in tissue engineering and regeneration

Tissue engineering is an interdisciplinary field of clinical applications and research focused on injured cells, tissues, and organ regeneration (63). In this discipline, scaffolds seeded with cells are used for the regeneration of damaged tissues (64). Recruiting cells for transplantation restrains proliferation and differentiation of somatic differentiated cells (65). Also, adult stem cells may maintain epigenetic modifications after reprogramming, which may limit their application (59). Stem cells isolated from embryonic and fetal tissues may facilitate these major advancements (65). These cells are safe for clinical application

given their genetic stability, differentiation capacity, and the epigenetic control system of early-passage AFSCs (66). Thus, AF is an important source of stem cells both in basic research and for regenerative medicine purposes. Engineered constructs using AFSCs promote the regeneration of damaged tissues (Table IV) (67-77).

Table IV. Differentiation potential of human amniotic epithelial stem cells

Author, year (Ref)	Regenerated tissue	Treatment
Kajiwara *et al*., 2017, Kunisaki, 2018 (67, 69)	Fetal	Congenital diaphragmatic hernia, abdominal wall defects, spinal bifida, and congenital heart
Cipriani *et al*., 2007 (68)	Peripheral and central nervous	Neurodegenerative disease such as cerebral ischemia
Di Baldassarre *et al*., 2018 (70)	Cardiac	Cardiomyoplasty
Chun *et al*., 2014 (71)	Skeletal muscle	Duchenne muscular dystrophy
Carraro *et al*., 2008 (72)	Lung	Lung-related disorders such as COVID-19
Morigi *et al*., 2014 (73)	Kidney	Acute ischemia-reperfusion and acute tubular necrosis
Wang *et al*., 2018 (74)	Hepatic	Liver fibrosis
Maraldi *et al*., 2013 (75)	Bone and cartilage	Extensive bone defects disease
Chang *et al*., 2018 (76)	Ovarian	Ovarian dystrophy and fertility
Gosemann *et al*., 2012 (77)	Inflammatory and autoimmune diseases	Graft-vs.-host disease, inflammatory bowel disease, experimental autoimmune encephalomyelitis, and systemic lupus erythematosus

1.9. Fetal tissue reconstruction

Early in fetal life, aberrant organogenesis can be caused by structural birth defects such as congenital diaphragmatic hernia, abdominal wall defects, congenital diaphragmatic hernia spinal bifida, congenital heart disease and spinal bifida. Using progenitor cells derived from AF is a novel therapeutic approach to organ regeneration in these pediatric diseases (67, 69). Diaphragmatic defect in neonatal lambs can be repaired with the mesenchymal amniocyte-based construct. Seeding a subpopulation of AFSCs onto polyglycolic acid/poly-4-hydroxyapatite, type I collagen, or polypropylene scaffolds could be a good construct for tissue-engineered diaphragmatic regeneration (78). AFSCs are preferred sources for fetal tissue reconstruction.

1.10. Neural tissue regeneration

AFSCs have been reported to be able to promote regeneration in central and peripheral nervous tissue. AFSCs become positive for nestin in a first induction phase and through time a fraction of the cells express dopaminergic markers and present a pyramidal morphology (79). AFSCs can be differentiated into the neuro-ectodermal lineage, exhibiting a barium-sensitive potassium current, expressing neuronal markers (e.g. GIRK potassium channels), and releasing glutamate after stimulation (80).

AFSCs can differentiate and migrate to a variety of brain regions including the hippocampus, periventricular areas, and the olfactory bulb when these cells are implanted into the lateral cerebral ventricles of neurodegenerative model

mice brains. When this has been studied, they are indistinguishable from surrounding murine cells (65). AFSCs that have been transplanted into the striatum of normal and ischemic rats have differentiated into neurons as well as astrocytes (68). AFSCs in fibrin glue or matrigel have been delivered into the crushed sciatic nerve where they promoted peripheral nerve regeneration (81). AFSCs promisingly promote peripheral and central nerve regeneration.

1.11. Cardiac regeneration

AFSCs can be differentiated into smooth muscle (smoothelin) cells, endothelial (angiopoietin, CD146), and cardiomyocyte (Nkx2.5, MLC-2v, GATA-4, β-MyHC) when implicated in cardiomyoplasty (70). AFSCs grow and proliferate, induce higher vascular density, promote attenuation of left ventricular remodeling, and thus lead to an improvement in cardiac function when implanted in the infarcted area of model mice (82). Transplantation of a cell sheet fragment composed of AFSCs and thermoresponsive methylcellulose extracellular matrices into the peri-ischemic area of an immune-suppressive rat model, remarkably enhanced vascular density, recovered wall thickness, and also substantially decreased the infarct size (83). Transplanted AFSCs can improve cardiac function.

1.12. Skeletal muscle regeneration

Differentiation of AFSCs into skeletal myogenic cells and skeletal muscle regeneration has been confirmed. These cells express desmin, troponin I, and α-actinin as skeletal cell-specific markers

in vitro (84-86). Transplantation of the cells into cardiotoxin-injured mice has demonstrated that they differentiate into myogenic precursor cells and aggregate with host myofibrils (87). Transplantation of the muscle progenitor cells that differentiated from AFSCs into the denervated external urethral sphincter enhances urodynamic action and expression of myogenic-related markers (71). These findings demonstrate that AFSCs are one of the most hopeful cells to treat skeletal muscle degenerative diseases such as Duchenne muscular dystrophy.

1.13. Lung epithelial regeneration

Transplantation of human AFSCs into an injured murine lung has been shown to cause differentiation into pulmonary lineages that express bronchiolar and alveolar markers and are associated with lung mucosal cells (72). It seems that AF is a valid resource for cell-based therapy for lung-related disorders.

1.14. Kidney regeneration

AFSCs can differentiate to renal fate in an ex vivo system. When they are transplanted into a mouse embryonic kidney they aggregate with the renal tissue, take part in nephrogenesis, and express molecular markers apecific for primary kidney differentiation like ZO-1, GDNF, and claudin (88). Injection of the cells into a damaged kidney has been shown to lead to ameliorates acute tubular necrosis in a mouse cognate model (73). When nephrectomy model rats were treated with AFSCs, a remarkable decrease was seen in proteinuria, macrophages, blood pressure, and expression of α-smooth muscle actin (89).

AFSCs with renal progenitor phenotype represent nephroprotective effects in model of acute ischemia-reperfusion. Treatment by AFSCs can cause a substantial decrease in serum creatinine level, hyaline cast formation, myofibroblasts, inflammatory cell infiltration, and tubular necrosis, and can increase the proliferation index (79).

1.15. Hepatic regeneration

AFSCs can be induced to differentiate into hepatocyte cells that express albumin, hepatocyte nuclear factor 4, alpha-fetoprotein, hepatocyte growth factor receptor, and the multidrug resistance membrane transporter MDR120, and secrete urea (90). Transplantation of AFSCs into liver fibrosis mouse models has revealed that the cells fuse with the recipient liver cells and improve hepatic function (74).

AFSC transplantation into fulminant hepatic failure mouse models can improve liver function and increase survival rates (91). AF is a promising origin of progenitor cells for liver cell transplantation and hepatocyte regeneration.

1.16. Bone and cartilage regeneration

AFSCs have been used to develop bone constructs using tissue engineering principles. The cells are cultured within the scaffold differentiated into osteoblastic or chondrocyte cells (92, 93). Differentiated cells produce mineralized calcium, and express and secrete alkaline phosphatase (ALP) as a surface marker of osteoblasts (94). AFSCs cultured within scaffolds such as grade poly-epsilon-caprolactone, poly-ε-caprolactone, poly-lactide-co-glycolide, fibrin, nonoscaffold, alginate/collagen, and combination of collagen, poly-D, L-lactic acid, and silk fibroin produce 3D mineralized high-density tissue-engineered bone both in vitro and in vivo (75). AF has been validated as an effective source for functional repair of extensive bone defects.

1.17. Ovarian regeneration

AFSCs have displayed important roles in the area of reproductive health. Derivation of oocyte-like cells from AFSCs with high efficiency present a new approach to the check of human germ cell development in vitro (95). These cells express germ cells' markers and restore folliculogenesis in germ cell-ablated mouse models (96). They can alleviate bovine ovarian dystrophy and restore fertility (76).

1.18. Regeneration of inflammatory and autoimmune diseases

Immunomodulatory effects of stem cells have been confirmed in different disease models such as graft-vs.-host disease, inflammatory bowel disease, experimental autoimmune encephalomyelitis, and systemic lupus erythematosus. AFSCs have remarkable immunomodulatory properties; they can be used for immunomodulatory cell therapy in autoimmune diseases and inflammatory conditions (77). They can prevent proliferation of T and B cell, macrophages, repress inflammatory properties of monocytes, neutrophils, natural killer cells and dendritic cells, and regulate the rule of T cells and anti-inflammatory M2 macrophages. These properties have enabled their use for the treatment of inflammatory and autoimmune-based diseases (97).

1.19. COVID-19

COVID-19 can cause an aggressive inflammatory and fibrotic response in both lungs. AF in the lungs of the unborn baby developed the lung-specific mesenchymal stem cells during pregnancy. This cells can be important for treating lung disease. A phase 1 trial for assessing the efficacy AFSCs to treat COVID-19 has been started by Monash Health researchers (98).

1.20. Clinical trial phase of AFSCs

Plasticity and immunomodulatory properties, of AFSCs have been candidates for treatment of different diseases. Previous preclinical studies have represented the AFSCs therapeutic potential in regenerative medicine. As of March 2021, 17 clinical trials about using these cells for curing different kinds of diseases were reported in the clinical trial databases Clinical Trials.gov and anzctr.org.au (Table V) (98).

Table V. Clinical trials utilizing AFSCs

Registration code	Disease	Results	Starting date
NCT00344708	Damaged ocular surfaces	Re-establish the integrity of ocular surface	2006
NCT02961712	Myelopathy	Improvement of Osame's Motor Disability score	2016
NCT03107975	Spastic cerebral palsy	Improvement in gross motor function	2017
NCT04414813	Parkinson's disease	Dopaminergic neurons differentiation	2019
ACTRN12618000076279*	Ischaemic stroke	Reducing infarct volume	2019
NCT02912104	Primary ovarian insufficiency	Transdifferentiated into granulosa cells	2016
NCT03223454	Asherman's syndrome	Improvement in endometrial thickness and fertility	2017
NCT03207412	Ovarian insufficiency	Improvement in mice fertility	2017
NCT03381807	Refractory severe intrauterine adhesion	Improvement in endometrial thickness and fertility	2017
NCT02959333	Bronchial fistula	Recovery of bronchial fistula	2016
ACTRN12614000174684	Bronchopulmonary dysplasia	Rescue lung injury	2014
ACTRN12620000676910 p**	COVID-19-related respiratory failure	Improved lung dysfunction	2019
NCT03031509	Nonunion of limb fracture	Osteogenic differentiation	2017
NCT03764228	Acute graft-vs.-host disease	Preventing acute graft-vs.-host disease	2018
ACTRN12616000437460	Hepatic fibrosis	Reduce liver fibrosis and stimulate regeneration of liver cells	2017
ACTRN12618001883202	Crohn's disease	Change in nature, severity or frequency of disease	2018

AFSCs: Amniotic fluid stem cells,*the cell source was human amniotic epithelial stem cells except the specified reference. Which was human amnion stem cells. **All clinical trials was in 1st stage except the specified reference which was the 2nd stage

2. Discussion

After the 10th-20th gestation wk, free diffusion happens between the fetus and AF through the placenta, fetal skin, and umbilical cord (4). At first, AF is mainly composed of water from the mother's body (98%) and the remaining 2% is salt and cells from the baby. But after the 12th-14th wk, it is also composed of carbohydrates, proteins, lipids, phospholipids, growth factors, and

urea, which after the 12th-14th wk that help the development of the fetus (99). During this period, AF composition is similar to that of fetal plasma, thus the analysis of AF composition can provide useful would represent worth information about of the pathological or physiological status of the fetus (1, 100).

AF also contains comprises a heterologous cell population from all 3 embryonic germ layers (101). It has been proposed stem cells that the biological and therapeutic characteristics of AF stem cells were be studied (99). These cells can be easily obtained during amniocentesis with low risk for the mother and the fetus, and grow in vitro (89).

AFSCs have genetic stability, non-tumorigenicity, anti-inflammatory properties, high proliferative capacity, angiogenic potential, growth factor secretion, immunomodulatory properties and low immunogenic activity. Studying AFSCs does not pose any ethical concerns for recruiting participants in in vivo experiments.

Therefore, they serve as a promising source of cells for tissue engineering applications in regenerative medicine (102). These cells can regenerate several tissues faults, such as fetal tissue, heart, the nervous system, kidneys, lungs, cartilage, bones, and ovary tissues. Accordingly, AFSCs are becoming a promising tool for the treatment of a wide range of congenital and acquired human disorders (99, 103).

3. Conclusion

In this review, we described AF as a fluid that surrounds the baby in the uterus. We explained the sources of AF and its vital functions in fetal development. We illustrated that it is composed of nutrients, hormones, and biochemical products. The appearance and volume of AF depend on gestational age. Finally, the survival of stem cells in the AF, their high proliferation rate, the substantial potential of differentiation, normal karyotype, and low immunogenicity were discussed. We elaborated on the potential of AFSCs to promote the regeneration of various tissue defects in vitro and in vivo.

Acknowledgments

Conflict of Interest

The authors declare that there is no conflict of interest.

References

[1] Geer LA, Pycke BFG, Sherer DM, Abulafia O, Halden RU. Use of amniotic fluid for determining pregnancies at risk of preterm birth and for studying diseases of potential environmental etiology. *Environ Res* 2015; 136: 470–481.

[2] Lim JJ, Koob TJ. Placental cells and tissues: The transformative rise in advanced wound care. In: Fonseca C. Worldwide wound healing-innovation in natural and conventional methods. London: InTech Open; 2016.

[3] Magann EF, Sandlin AT, Ounpraseuth ST. Amniotic fluid and the clinical relevance of the sonographically estimated amniotic fluid volume: Oligohydramnios. *J Ultrasound Med* 2011; 30: 1573–1585.

[4] Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: Not just fetal urine anymore. *J Perinatol* 2005; 25: 341–348.

[5] Dubil EA, Magann EF. Amniotic fluid as a vital sign for fetal wellbeing. *Australas J Ultrasound Med* 2013; 16: 62–70.

[6] Sha X-y, Xiong Z-f, Liu H-s, Di X-d, Ma T-h. Maternal-fetal fluid balance and aquaporins: From molecule to physiology. *Acta Pharmacol Sin* 2011; 32: 716–720.

[7] van Otterlo LC, Wladimiroff JW, Wallenburg HC. Relationship between fetal urine production and amniotic fluid volume in normal pregnancy and pregnancy complicated by diabetes. *Br J Obstet Gynaecol* 1977; 84: 205–209.

[8] Abramovich DR, Garden A, Jandial L, Page KR. Fetal swallowing and voiding in relation to hydramnios. *Obstet Gynecol* 1979; 54: 15–20.

[9] Brace RA. Physiology of amniotic fluid volume regulation. *Clin Obstet Gynecol* 1997; 40: 280–289.

[10] van der Knoop BJ, van Schie PEM, Vermeulen RJ, Pistorius LR, van Weissenbruch MM, de Vries JIP. Effect of (minor or major) maternal trauma on fetal motility: A prospective study. *Early Hum Dev* 2015; 91: 511–517.

[11] Akinbi HT, Narendran V, Pass AK, Markart P, Hoath SB. Host defense proteins in vernix caseosa and amniotic fluid. *Am J Obstet Gynecol* 2004; 191: 2090–2096.

[12] Rashid H, Kagami M, Ferdous F, Ma E, Terao T, Hayashi T, et al. Temperature during pregnancy influences the fetal growth and birth size. *Trop Med Health* 2016; 45: 1.

[13] Dawood MY. Hormones in amniotic fluid. *Am J Obstet Gynecol* 1977; 128: 576–583.

[14] Oliveira FR, Barros EG, Magalhaes JA. Biochemical profile of amniotic fluid for the assessment of fetal and renal development. *Braz J Med Biol Res* 2002; 35: 215–222.

[15] Bauk FA, Moron AF, Novo NF, Juliano Y, Rodrigues EB, Kulay Jr L. [A comparative study of the sodium, potassium, urea, creatinine, and uric acid concentrations in the human amniotic fluid between weeks 15–20 and 38–42]. *Rev Assoc Med Bras* 1996; 42: 7–10. (in Portuguese)

[16] Ghaderi Sh, Soheili Z-S, Ahmadieh H, Davari M, Sanie Jahromi F, Samie S, et al. Human amniotic fluid promotes retinal pigmented epithelial cells' trans-differentiation into rod photoreceptors and retinal ganglion cells. *Stem Cells Dev* 2010; 20: 1615–1625.

[17] Sanie-Jahromi F, Ahmadieh H, Soheili Z-S, Davari M, Ghaderi S, Kanavi MR, et al. Enhanced generation of retinal progenitor cells from human retinal pigment epithelial cells induced by amniotic fluid. *BMC Res Notes* 2012; 5: 182.

[18] Davari M, Soheili Z-S, Ahmadieh H, Sanie-Jahromi F, Ghaderi Sh, Rezaei Kanavi M, et al. Amniotic fluid promotes the appearance of neural retinal progenitors and neurons in human RPE cell cultures. *Mol Vis* 2013; 19: 2330–2342.

[19] Verpoest MJ, Seelen JC, Westerman CF. Changes in appearance of amniotic fluid during pregnancy - the macroscore. *J Perinat Med* 1976; 4: 12–25.

[20] Zaretsky MV, McIntire DD, Reichel TF, Twickler DM. Correlation of measured amnionic fluid volume to sonographic and magnetic resonance predictions. *Am J Obstet Gynecol* 2004; 191: 2148–2153.

[21] Bromley B, Shipp TD, Benacerraf B. Assessment of the third-trimester fetus using 3-dimensional volumes: A pilot study. *J Clin Ultrasound* 2007; 35: 231–237.

[22] Brace RA, Wolf EJ. Normal amniotic fluid volume changes throughout pregnancy. *Am J Obstet Gynecol* 1989; 161: 382–388.

[23] Petrozella LN, Dashe JS, McIntire DD, Leveno KJ. Clinical significance of borderline amniotic fluid index and oligohydramnios in preterm pregnancy. *Obstet Gynecol* 2011; 117: 338–342.

[24] de Tejada BM, Boulvain M, Dumps P, Bischof P, Meisser A, Irion O. Can we improve the diagnosis of rupture of membranes? The value of insulin-like growth factor binding protein-1. *BJOG* 2006; 113: 1096–1099.

[25] Storness-Bliss C, Metcalfe A, Simrose R, Wilson RD, Cooper SL. Correlation of residual amniotic fluid and perinatal outcomes in periviable preterm premature rupture of membranes. *J Obstet Gynaecol Can* 2012; 34: 154–158.

[26] Brizot ML, Liao AW, Nomura RM, Francisco RPV, Zugaib M. Changes in amniotic fluid index after maternal oral hydration in pregnancies with fetal gastroschisis: Initial observations. *Fetal Diagn Ther* 2010; 28: 87–91.

[27] Oyelese Y. Placenta, umbilical cord and amniotic fluid: The not-less-important accessories. *Clin Obstet Gynecol* 2012; 55: 307–323.

[28] Casey BM, McIntire DD, Bloom SL, Lucas MJ, Santos R, Twickler DM, et al. Pregnancy outcomes after antepartum diagnosis of oligohydramnios at or beyond 34 weeks' gestation. *Am J Obstet Gynecol* 2000; 182: 909–912.

[29] Leibovitch L, Kuint J, Rosenfeld E, Schushan-Eisen I, Weissmann-Brenner A, Maayan-Metzger A. Short-term outcome among term singleton infants with intrapartum oligohydramnios. *Acta Paediatr* 2012; 101: 727–730.

[30] Chavda RJ, Saini HB. A prospective clinical study of feto-maternal outcome in pregnancies with abnormal liquor volume. *Int J Reprod Contracept Obstet Gynecol* 2016; 3: 181–184.

[31] Baron C, Morgan MA, Garite TJ. The impact of amniotic fluid volume assessed intrapartum on perinatal outcome. *Am J Obstet Gynecol* 1995; 173: 167–174.

[32] Stevenson RE, Hall JG, Everman DB, Solomon BD. Human malformations and related anomalies. 3rd Ed. UK: Oxford University Press; 2015.

[33] Magann EF, Doherty DA, Lutgendorf MA, Magann MI, Chauhan SP, Morrison JC. Peripartum outcomes of high-risk pregnancies complicated by oligo-and polyhydramnios: A prospective longitudinal study. *J Obstet Gynaecol Res* 2010; 36: 268–277.

[34] Leibovitch L, Schushan-Eisen I, Kuint J, Weissmann-Brenner A, Maayan-Metzger A. Short-term outcome for term and near-term singleton infants with intrapartum polyhydramnios. *Neonatology* 2012; 101: 61–67.

[35] Perović M, Garalejić E, Gojnić M, Arsić B, Pantić I, Bojović DJ, et al. Sensitivity and specificity of ultrasonography as a screening tool for gestational diabetes mellitus. *J Matern Fetal Neonatal Med* 2012; 25: 1348–1353.

[36] Hamza A, Herr D, Solomayer EF, Meyberg-Solomayer G. Polyhydramnios: Causes, diagnosis and therapy. *Geburtshilfe Frauenheilkd* 2013; 73: 1241–1246.

[37] Prusa A-R, Hengstschlager M. Amniotic fluid cells and human stem cell research: A new connection. *Med Sci Monit* 2002; 8: RA253–RA257.

[38] Cananzi M, De Coppi P. CD117(+) amniotic fluid stem cells: State of the art and future perspectives. *Organogenesis* 2012; 8: 77–88.

[39] Siegel N, Rosner M, Hanneder M, Freilinger A, Hengstschläger M. Human amniotic fluid stem cells: A new perspective. *Amino Acids* 2008; 35: 291–293.

[40] Streubel B, Martucci-Ivessa G, Fleck T, Bittner R. [In vitro transformation of amniotic cells to muscle cells–background and outlook]. *Wien Med Wochenschr* 1996; 146: 216–217. (in German)

[41] In't Anker PS, Scherjon SA, Kleijburg-Van der Keur C, Noort WA, Claas FH, Willemze R, et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. *Blood* 2003; 102: 1548–1549.

[42] Prusa A-R, Marton E, Rosner M, Bernaschek G, Hengstschläger M. Oct-4-expressing cells in human amniotic fluid: A new source for stem cell research? *Hum Reprod* 2003; 18: 1489–1493.

[43] Karlmark KR, Freilinger A, Marton E, Rosner M, Lubec G, Hengstschläger M. Activation of ectopic Oct-4 and Rex-1 promoters in human amniotic fluid cells. *Int J Mol Med* 2005; 16: 987–992.

[44] Ditadi A, de Coppi P, Picone O, Gautreau L, Smati R, Six E, et al. Human and murine amniotic fluid c-Kit+Lin- cells display hematopoietic activity. *Blood* 2009; 113: 3953–3960.

[45] Crane JF, Trainor PA. Neural crest stem and progenitor cells. *Annu Rev Cell Dev Biol* 2006; 22: 267–286.

[46] Roobrouck VD, Ulloa-Montoya F, Verfaillie CM. Self-renewal and differentiation capacity of young and aged stem cells. *Exp Cell Res* 2008; 314: 1937–1944.

[47] Sessarego N, Parodi A, Podestà M, Benvenuto F, Mogni M, Raviolo V, et al. Multipotent mesenchymal stromal cells from amniotic fluid: Solid perspectives for clinical application. *Haematologica* 2008; 93: 339–346.

[48] Schiavo AA, Franzin C, Albiero M, Piccoli M, Spiro G, Bertin E, et al. Endothelial properties of third-trimester amniotic fluid stem cells cultured in hypoxia. *Stem Cell Res Ther* 2015; 6: 209.

[49] Chen J, Lu Zh, Cheng D, Peng Sh, Wang H. Isolation and characterization of porcine amniotic fluid-derived multipotent stem cells. *PLoS One* 2011; 6: e19964.

[50] Moschidou D, Mukherjee S, Blundell MP, Drews K, Jones GN, Abdulrazzak H, et al. Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. *Mol Ther* 2012; 20: 1953–1967.

[51] Hoseini SM, Montazeri F, Moghaddam-Matin M, Bahrami AR, Heidarian Meimandi H, Ghasemi-Esmailabad S, et al. Comparison of chromosomal instability of human amniocytes in primary and long-term cultures in AmnioMAX II and DMEM media: A cross-sectional study. *Int J Reprod Biomed* 2020; 18: 885–898.

[52] Moschidou D, Mukherjee S, Blundell MP, Jones GN, Atala AJ, Thrasher AJ, et al. Human mid-trimester amniotic fluid stem cells cultured under embryonic stem cell conditions with valproic acid acquire pluripotent characteristics. *Stem Cells Dev* 2013; 22: 444–458.

[53] Hoseini SM, Sheikhha MH, Kalantar SM, Matin MM, Aflatoonian B, Bahrami AR, et al. A comparative analysis of immunomodulatory genes in two clonal subpopulations of CD90(+) amniocytes isolated from human amniotic fluid. *Placenta* 2020; 101: 234–241.

[54] Kim J, Lee Y, Kim H, Hwang KJ, Kwon HC, Kim SK, et al. Human amniotic fluid-derived stem cells have characteristics of multipotent stem cells. *Cell Prolif* 2007; 40: 75–90.

[55] Torricelli F, Brizzi L, Bernabei PA, Gheri G, Di SL, Nutini L, et al. Identification of hematopoietic progenitor cells in human amniotic fluid before the 12th week of gestation. *Ital J Anat Embryol* 1993; 98: 119–126.

[56] Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. *Hum Reprod* 2004; 19: 1450–1456.

[57] McLaughlin D, Tsirimonaki E, Vallianatos G, Sakellaridis N, Chatzistamatiou T, Stavropoulos-Gioka C, et al. Stable expression of a neuronal dopaminergic progenitor phenotype in cell lines derived from human amniotic fluid cells. *J Neurosci Res* 2006; 83: 1190–1200.

[58] Gosden C, Brock DJ. Combined use of alphafetoprotein and amniotic fluid cell morphology in early prenatal diagnosis of fetal abnormalities. *J Med Genet* 1978; 15: 262–270.

[59] Loukogeorgakis SP, De Coppi P. Concise review: Amniotic fluid stem cells: The known, the unknown, and potential regenerative medicine applications. *Stem Cells* 2017; 35: 1663–1673.

[60] Cananzi M, Atala A, De Coppi P. Stem cells derived from amniotic fluid: New potentials in regenerative medicine. *Reprod Biomed Online* 2009; 18 (Suppl.): 17–27.

[61] Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. *Stem Cells* 2007; 25: 646–654.

[62] Baghaban Eslaminejad M, Jahangir S. Amniotic fluid stem cells and their application in cell-based tissue regeneration. *Int J Fertil Steril* 2012; 6: 147–156.

[63] Daar AS, Greenwood HL. A proposed definition of regenerative medicine. *J Tissue Eng Regen Med* 2007; 1: 179–184.

[64] Hipp J, Atala A. Sources of stem cells for regenerative medicine. *Stem Cell Rev* 2008; 4: 3–11.

[65] National Research Counsil and Institute of Medicine Committee on the Biological and Biomedical Applications of Stem Cell Research. Stem cells and the future of regenerative medicine. Washington: DC: The National Academies Press; 2002.

[66] Stultz BG, McGinnis K, Thompson EE, Surdo JLL, Bauer SR, Hursh DA. Chromosomal stability of mesenchymal stromal cells during in vitro culture. *Cytotherapy* 2016; 18: 336–343.

[67] Kajiwara K, Tanemoto T, Wada S, Karibe J, Ihara N, Ikemoto Y, et al. Fetal therapy model of myelomeningocele with three-dimensional skin using amniotic fluid cell-derived induced pluripotent stem cells. *Stem Cell Reports* 2017; 8: 1701–1713.

[68] Cipriani S, Bonini D, Marchina E, Balgkouranidou I, Caimi L, Zucconi GG, et al. Mesenchymal cells from human amniotic fluid survive and migrate after transplantation into adult rat brain. *Cell Biol Int* 2007; 31: 845–850.

[69] Kunisaki SM. Amniotic fluid stem cells for the treatment of surgical disorders in the fetus and neonate. *Stem Cells Transl Med* 2018; 7: 767–773.

[70] Di Baldassarre A, D'Amico MA, Izzicupo P, Gaggi G, Guarnieri S, Mariggiò MA, et al. Cardiomyocytes derived from human cardiopoietic amniotic fluids. *Sci Rep* 2018; 8: 12028.

[71] Chun SY, Kwon JB, Chae SY, Lee JK, Bae Js, Kim BS, et al. Combined injection of three different lineages of early-differentiating human amniotic fluid-derived cells restores urethral sphincter function in urinary incontinence. *BJU Int* 2014; 114: 770–783.

[72] Carraro G, Perin L, Sedrakyan S, Giuliani S, Tiozzo C, Lee J, et al. Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. *Stem Cells* 2008; 26: 2902–2911.

[73] Morigi M, De Coppi P. Cell therapy for kidney injury: Different options and mechanisms-mesenchymal and amniotic fluid stem cells. *Nephron Exp Nephrol* 2014; 126: 59–63.

[74] Wang MF, Li YB, Gao XJ, Zhang HY, Lin S, Zhu YY. Efficacy and safety of autologous stem cell transplantation for decompensated liver cirrhosis: A retrospective cohort study. *World J Stem Cells* 2018; 10: 138–145.

[75] Maraldi T, Riccio M, Pisciotta A, Zavatti M, Carnevale G, Beretti F, et al. Human amniotic fluid-derived and dental pulp-derived stem cells seeded into collagen scaffold repair critical-size bone defects promoting vascularization. *Stem Cell Res Ther* 2013; 4: 53.

[76] Chang LB, Peng SY, Chou CJ, Chen YJ, Shiu JS, Tu PA, et al. Therapeutic potential of amniotic fluid stem cells to treat bilateral ovarian dystrophy in dairy cows in a subtropical region. *Reprod Domest Anim* 2018; 53: 433–441.

[77] Gosemann JH, Kuebler JF, Pozzobon M, Neunaber C, Hensel JHK, Ghionzoli M, et al. Activation of regulatory T cells during inflammatory response is not an exclusive property of stem cells. *PLoS One* 2012; 7: e35512.

[78] Kunisaki SM, Fuchs JR, Kaviani A, Oh JT, LaVan DA, Vacanti JP, et al. Diaphragmatic repair through fetal tissue engineering: A comparison between mesenchymal amniocyte–and myoblast-based constructs. *J Pediatr Surg* 2006; 41: 34–39.

[79] da Cunha MGMCM, Zia S, Beckmann DV, Carlon MS, Arcolino FO, Albersen M, et al. Vascular endothelial growth factor up-regulation in human amniotic fluid stem cell enhances nephroprotection after ischemia-reperfusion injury in the rat. *Crit Care Med* 2017; 45: e86–e96.

[80] Cananzi M, Atala A, De Coppi P. Stem cells derived from amniotic fluid: New potentials in regenerative medicine. *Reprod Biomed Online* 2009; 18: 17–27.

[81] Pan HC, Yang DY, Chiu YT, Lai SZ, Wang YC, Chang MH, et al. Enhanced regeneration in injured sciatic nerve by human amniotic mesenchymal stem cell. *J Clin Neurosci* 2006; 13: 570–575.

[82] Yeh YCh, Wei HJ, Lee WY, Yu CL, Chang Y, Hsu LW, et al. Cellular cardiomyoplasty with human amniotic fluid stem cells: In vitro and in vivo studies. *Tissue Eng Part A* 2010; 16: 1925–1936.

[83] Yeh YCh, Lee WY, Yu ChL, Hwang ShM, Chung MF, Hsu LW, et al. Cardiac repair with injectable cell sheet fragments of human amniotic fluid stem cells in an immune-suppressed rat model. *Biomaterials* 2010; 31: 6444–6453.

[84] Ma X, Zhang Sh, Zhou J, Chen B, Shang Y, Gao T, et al. Clone-derived human AF-amniotic fluid stem cells are capable of skeletal myogenic differentiation in vitro and in vivo. *J Tissue Eng Regen Med* 2012; 6: 598–613.

[85] Bajek A, Olkowska J, Walentowicz-Sadłecka M, Sadłecki P, Grabiec M, Porowińska D, et al. Human adipose-derived and amniotic fluid-derived stem cells: A preliminary in vitro study comparing myogenic differentiation capability. *Med Sci Monit* 2018; 24: 1733–1741.

[86] Chun SY, Cho DH, Chae SY, Choi KH, Lim HJ, Yoon GS, et al. Human amniotic fluid stem cell-derived muscle progenitor cell therapy for stress urinary incontinence. *J Korean Med Sci* 2012; 27: 1300–1307.

[87] Kim JA, Shon YH, Lim JO, Yoo JJ, Shin HI, Park EK. MYOD mediates skeletal myogenic differentiation of human amniotic fluid stem cells and regeneration of muscle injury. *Stem Cell Res Ther* 2013; 4: 147.

[88] Perin L, Giuliani S, Jin D, Sedrakyan S, Carraro G, Habibian R, et al. Renal differentiation of amniotic fluid stem cells. *Cell Prolif* 2007; 40: 936–948.

[89] Noronha IL, Cavaglieri RC, Janz FL, Duarte SA, Lopes MA, Zugaib M, et al. The potential use of stem cells derived from human amniotic fluid in renal diseases. *Kidney Int Suppl (2011)* 2011; 1: 77–82.

[90] Marongiu F, Gramignoli R, Dorko K, Miki T, Ranade AR, Serra MP, et al. Hepatic differentiation of amniotic epithelial cells. *Hepatology* 2011; 53: 1719–1729.

[91] Zheng YB, Zhang XH, Huang ZhL, Lin ChSh, Lai J, Gu YR, et al. Amniotic-fluid-derived mesenchymal stem cells overexpressing interleukin-1 receptor antagonist improve fulminant hepatic failure. *PLoS One* 2012; 7: e41392.

[92] Kolambkar YM, Peister A, Soker S, Atala A, Guldberg RE. Chondrogenic differentiation of amniotic fluid-derived stem cells. *J Mol Histol* 2007; 38: 405–413.

[93] Peister A, Woodruff MA, Prince JJ, Gray DP, Hutmacher DW, Guldberg RE. Cell sourcing for bone tissue engineering: Amniotic fluid stem cells have a delayed, robust differentiation compared to mesenchymal stem cells. *Stem Cell Res* 2011; 7: 17–27.

[94] De Coppi P, Bartsch Jr G, Siddiqui MM, Xu T, Santos CC, Perin L, et al. Isolation of amniotic stem cell lines with potential for therapy. *Nat Biotechnol* 2007; 25: 100–106.

[95] Yu X, Wang N, Qiang R, Wan Q, Qin M, Chen Sh, et al. Human amniotic fluid stem cells possess the potential to differentiate into primordial follicle oocytes in vitro. *Biol Reprod* 2014; 90: 73–81.

[96] Zhang Q, Bu Sh, Sun J, Xu M, Yao X, He K, et al. Paracrine effects of human amniotic epithelial cells protect against chemotherapy-induced ovarian damage. *Stem Cell Res Ther* 2017; 8: 270.

[97] Magatti M, Vertua E, Cargnoni A, Silini A, Parolini O. The immunomodulatory properties of amniotic cells: The two sides of the coin. *Cell Transplant* 2018; 27: 31–44.

[98] Qiu Ch, Ge Zh, Cui W, Yu L, Li J. Human amniotic epithelial stem cells: A promising seed cell for clinical applications. *Int J Mol Sci* 2020; 21: 7730

[99] Yu L. Human amniotic fluid-derived and amniotic membrane-derived stem cells. In: Zhao RC. Stem cells: Basics and clinical translation. China: Shanghai Jiao Tong University Press; 2015: 29–66.

[100] Cho Ch-KJ, Shan ShJ, Winsor EJ, Diamandis EP. Proteomics analysis of human amniotic fluid. *Mol Cell Proteomics* 2007; 6: 1406–1415.

[101] Da Sacco S, Sedrakyan S, Boldrin F, Giuliani S, Parnigotto P, Habibian R, et al. Human amniotic fluid as a potential new source of organ specific precursor cells for future regenerative medicine applications. *J Urol* 2010; 183: 1193–1200.

[102] Borlongan CV. Amniotic fluid as a source of engraftable stem cells. *Brain Circ* 2017; 3: 175.

[103] Moodley Y, Ilancheran S, Samuel Ch, Vaghjiani V, Atienza D, Williams ED, et al. Human amnion epithelial cell transplantation abrogates lung fibrosis and augments repair. *Am J Respir Crit Care Med* 2010; 182: 643–651.